Literature DB >> 11025630

Pre and post betahistine therapy 99m Tc - HMPAO brain spect studies in patients with vertigo.

B A Krishna1, M V Kirtane, T Sangeeta, G Gopinath.   

Abstract

Vertebro basilar insufficiency (VBI) is a well known cause of vertigo. Brain Single Photon Emission Computed Tomography (SPECT) is an important diagnostic tool to detect and to quantitate the perfusion abnormalities in different areas of the brain. Effect of an antivertigo drug Betahistine on improving the hypoperfusion in different areas of the brain in vertigo patients was studied using brain SPECT. Betahistine at a dose of 16 mg three times daily was shown to improve perfusion in the hypoperfused areas of the brain resulting in relief from symptoms of vertigo. The cerebellar region, which is the most important area involved in vertigo patients with vascular pathology, showed almost complete normalisation of perfusion following Betahistine therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025630

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  4 in total

1.  Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.

Authors:  Jozef J P Nauta
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-19       Impact factor: 2.503

2.  A practical cochlear implant for India.

Authors:  William F House; Khandhar Vinod
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2003-03

3.  Cerebral perfusion abnormalities in patients with persistent postural-perceptual dizziness (PPPD): a SPECT study.

Authors:  Seunghee Na; Jooyeon Jamie Im; Hyeonseok Jeong; Eek-Sung Lee; Tae-Kyeong Lee; Yong-An Chung; In-Uk Song
Journal:  J Neural Transm (Vienna)       Date:  2018-10-31       Impact factor: 3.575

4.  Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière's Disease.

Authors:  Augusto Pietro Casani; Elena Navari; Giorgio Guidetti; Michel Lacour
Journal:  Int J Otolaryngol       Date:  2018-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.